H-CYTE, Inc. announced that it entered into a securities purchase agreement with two accredited investors and issued 112,500 shares of common stock and warrants to purchase 66,250 shares of Common Stock exercisable at $2.50 per share for gross proceeds of $225,000 on September 29, 2022. All of the shares described in this offered and issued to accredited investors in reliance upon exemptions from the registration requirements under Section 4(a)(2) under the Securities Act of 1933, as amended (“Securities Act”), and Rule 506 of Regulation D promulgated thereunder. No finders fees is paid in the transaction.